Instrument Inactif

Communiqués IP GROUP Swiss Exchange

Actions

IPO

GB00B128J450

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

IP : STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024	03/06	PU
IP GROUP INVESTORS THROW STONES AT FLINT	30/05	AQ
Ultraleap Launches Hyperion: the next generation tracking software platform	10/05	PU
IP : C-Capture Launches Innovative Carbon Capture Trial for Cement Industry	10/05	PU
IP : Bramble Energy achieves milestone in hydrogen fuel cell production, advancing UK’s electrified automotive future	09/05	PU
IP : Hysata announces $111m USD Series B investment round	09/05	PU
Finguerra-DuCharme And Garber Write About Key Fashion Trademark Cases	03/05	AQ
IP : Genomics plc and GSK establish precision medicine collaboration to assess polygenic risk scores in clinical trial design	30/04	PU
IP : Notice of the 2024 Annual General Meeting	24/04	PU
IP : First Light Fusion - First Light Founder moves into new science-focused role with Acting CEO appointed	22/04	PU
IP : Kynos Therapeutics announces positive top line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement	22/04	PU
IP : First Light Fusion solves major engineering challenge in the design of an Inertial Confinement Fusion pilot power plant	03/04	PU
IP : Tissue Regenix Group plc - Final results for the year ended 31 December 2023	19/03	PU
Mission Therapeutics raises GBP25.2 million to progress clinical candidates in the area of mitophagy	15/03	AQ
IP : Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy	14/03	PU
IP : Moa Techology - Moa to develop next-gen bioherbicides in new 10-year commercial partnership with Croda	13/03	PU
IP : Oxford Nanopore Technologies and SeqOne partner to support interpretation of nanopore sequencing in clinical use	12/03	PU
IP : Quantum Dice And HSBC Collaborate On The Use Of QRNGs To Enhance Financial Monte Carlo Simulations	05/03	PU
IP : Oxford Nanopore Technologies plc - Directorate Change	01/03	PU
IP : Oxford Nanopore Technologies plc - Appoints Two Non-Executive Directors	19/12	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués IP GROUP Swiss Exchange

Actions

IPO

GB00B128J450

Communiqués

Filtres